TITLE

Current Status of Medical Treatment for Inflammatory Bowel Disease

AUTHOR(S)
Goldstein, Franz
PUB. DATE
December 1983
SOURCE
American Journal of Gastroenterology;Dec1983, Vol. 78 Issue 12, p841
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Reviews the status of medical treatment for inflammatory bowel disease (IBD), particularly Crohn's disease (CD), as of December 1983. Therapeutic mainstay for the majority of IBD patients medically treatable; Basic principles of CD treatment; Differences between CD and ulcerative colitis with regard to treatment.
ACCESSION #
17147768

 

Related Articles

  • Calidad en el manejo de enfermedad inflamatoria intestinal. Juliao Baños, Fabián // Revista Colombiana de Gastroenterología;Jul2011, Vol. 26 Issue 3, p211 

    The management of patients with both types of inflammatory bowel disease (IBD), Ulcerative Colitis and Crohn's Disease, varies in medical centers around the world. Recognition of this variability in patient management is the initial step in improving the quality of care of IBD patients. The need...

  • New biological agents for the treatment of the "high risk" IBD patients. GUIDI, L.; MARZO, M.; FELICE, C.; MOCCI, G.; SPARANO, L.; PUGLIESE, D.; DE VITIS, I.; PAPA, A.; ARMUZZI, A. // European Review for Medical & Pharmacological Sciences;2010, Vol. 14 Issue 4, p342 

    Background: Several new biological drugs have been introduced in the last decade or are under investigation for the treatment of IBD. They include anti TNFα agents, anti adhesion molecules, anti IL-12/23, anti IL-6R and others. Their role in IBD therapy will be discussed in regard of the...

  • Infliximab: A Review of Its Use in the Treatment of Inflammatory Bowel Disease. Marzo, Manuela; Felice, Carla; Rapaccini, Gian Lodovico; Guidi, Luisa; Armuzzi, Alessandro // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p15 

    Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has changed the management of inflammatory bowel diseases. Our review describes its mean clinical and pharmacological features, in order to resume its efficacy in induction and maintenance of clinical...

  • Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner? Fiorino, Gionata; Rovida, Serena; Correale, Carmen; Malesci, Alberto; Danese, Silvio // Current Drug Targets;Feb2010, Vol. 11 Issue 2, p249 

    Inflammatory bowel diseases (IBD) are idiopathic chronic inflammations: the etiology of Crohn's disease (CD) and ulcerative colitis (UC) is still largely unknown. Environmental and genetic factors in combination with the microbial flora or specific microorganisms trigger an event, leading to the...

  • Telemanagement for Inflammatory Bowel Disease. Cross Jr., Raymond K. // Gastroenterology & Hepatology;Apr2014, Vol. 10 Issue 4, p255 

    An interview with physician Raymond K. Cross Jr. is presented. He discusses about how telemedicine can be used in the management of inflammatory bowel disease (IMD) and its impact on office-based practice. He explains about the Home Automated Telemanagement (HAT) system, an example of...

  • Epidemiologic study of 80 Patients with Ulcerative Colitis refereed to Imam Hospital in Ardabil City during 2004-2010. Amani, Firouz; Sadeghi Movahed, Vahid; Tabarraie, Yaser // Advances in Bioresearch;Mar2014, Vol. 5 Issue 1, p131 

    Ulcerative colitis is one of the inflammatory bowel diseases with unknown etiology. Genetic and environmental factors are thought to be effective in this disease. The aim of this study is to assessment of demographic features and clinical symptoms of Ulcerative colitis patients refereed to Emam...

  • Genes, Microbes, and T Cells – New Therapeutic Targets in Crohn's Disease. Elson, Charles O. // New England Journal of Medicine;2/21/2002, Vol. 346 Issue 8, p614 

    The article focuses on issues related to the treatment of Crohn's disease. Crohn's disease and ulcerative colitis, jointly known as inflammatory bowel disease, is said to affect more than one million people in the U.S. In 1996, a gene, called NOD2, conferring susceptibility to Crohn's disease...

  • Current Therapeutic Approaches in Inflammatory Bowel Disease. Sohrabpour, Amir Ali; Malekzadeh, Reza; Keshavarzian, Ali // Current Pharmaceutical Design;11/28/2010, Vol. 16 Issue 33, p3668 

    No abstract available.

  • Use of biological therapy during pregnancy in the treatment of IBD. Thomas, Rosemarie // Gastrointestinal Nursing;Apr2009, Vol. 7 Issue 3, pS4 

    Ulcerative colitis and Crohn's disease often occur in the younger population, which means they are likely to affect women of child-bearing age. Infliximab and adalimumab, both biological therapies, are being increasingly used to treat moderate-to-severe inflammatory bowel disease (IBD) when...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics